Swissmedic Accepts Marketing Authorization Application for Piflufolastat (18F) for Prostate Cancer
Swissmedic has accepted for review a marketing authorization application seeking the approval of Piflufolastat (18F) for prostate cancer.
Swissmedic has accepted for review a marketing authorization application seeking the approval of Piflufolastat (18F) for prostate cancer.
Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.
Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.
Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.
The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.
Pelotonia is a community that is determined to see an end to cancer. Together, we’ve saved countless lives. Help us save more.
A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously…
An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) Patient-Focused Drug Development (PFDD) program welcomes you to the Clinical Outcome Assessment in…
Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth…